首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2032篇
  免费   2篇
化学工业   17篇
能源动力   1篇
轻工业   1篇
石油天然气   1篇
无线电   1篇
一般工业技术   22篇
冶金工业   1989篇
自动化技术   2篇
  2019年   4篇
  2018年   2篇
  2017年   1篇
  2015年   2篇
  2014年   1篇
  2013年   5篇
  2012年   2篇
  2011年   2篇
  2010年   2篇
  2007年   3篇
  2005年   4篇
  2004年   1篇
  2003年   3篇
  2002年   9篇
  2000年   2篇
  1999年   68篇
  1998年   607篇
  1997年   347篇
  1996年   206篇
  1995年   109篇
  1994年   102篇
  1993年   127篇
  1992年   17篇
  1991年   26篇
  1990年   23篇
  1989年   37篇
  1988年   34篇
  1987年   42篇
  1986年   33篇
  1985年   19篇
  1983年   6篇
  1982年   6篇
  1981年   9篇
  1980年   10篇
  1979年   1篇
  1978年   2篇
  1977年   49篇
  1976年   104篇
  1975年   3篇
  1961年   1篇
  1955年   3篇
排序方式: 共有2034条查询结果,搜索用时 15 毫秒
81.
82.
A 10-center cooperative clinical study with a new formulation of epirubicin hydrochloride injectable solution (Epirubicin-RTU) was conducted in patients with breast cancer. One course of treatment consisted of one intravenous administration of Epirubicin-RTU at the dose of 60 mg/m2 followed by a 3-week drug-free interval and concomitant daily administration of oral cyclophosphamide at 100 mg/day during the period between Days 1 through 14. At least, two courses of treatment were given. Among 20 registered cases, all 20 cases were eligible and 16 cases completed the whole course of the study. In 16 completers, PR was observed in 5 cases, indicating the efficacy rate of 31.3% (5/16).. No local irritation was observed at the injection sites. Adverse reactions frequently observed were leukopenia, neutropenia, anorexia, alopecia, and nausea/vomiting, which were all reversible and tolerable. From the above results, Adverse reactions both locally and systemically were tolerable. Intravenous administration of Epirubicin-RTU was considered to be useful for the treatment of breast cancer.  相似文献   
83.
The role of practice guidelines in malpractice litigation has been discussed in some theoretical detail. Little information is available, however, on how courts use guidelines or on the effort of state legislatures to explicitly link guideline compliance with malpractice defenses. We review all relevant case law and legislative enactments to shed light on the influence of medical malpractice on guidelines. We also use data from a nationwide survey of malpractice attorneys to supplement our legal analysis. Although guidelines are being used for both inculpatory and exculpatory purposes in common-law litigation (a two-way street), legislatures are interested in applying them only for exculpatory purposes (a one-way street).  相似文献   
84.
85.
86.
87.
88.
89.
The social environment and normative structure surrounding drinking have a reciprocal relationship in determining adolescent drinking patterns in high school and college.  相似文献   
90.
Calcium phosphate bone cements (CPBCs) are osteotransductive, i.e. after implantation in bone they are transformed into new bone tissue. Furthermore, due to the fact that they are mouldable, their osteointegration is immediate. Their chemistry has been established previously. Some CPBCs contain amorphous calcium phosphate (ACP) and set by a sol-gel transition. The others are crystalline and can give as the reaction product dicalcium phosphate dihydrate (DCPD), calcium-deficient hydroxyapatite (CDHA), carbonated apatite (CA) or hydroxyapatite (HA). Mixed-type gypsum-DCPD cements are also described. In vivo rates of osteotransduction vary as follows: gypsum-DCPD > DCPD > CDHA approximately CA > HA. The osteotransduction of CDHA-type cements may be increased by adding dicalcium phosphate anhydrous (DCP) and/or CaCO3 to the cement powder. CPBCs can be used for healing of bone defects, bone augmentation and bone reconstruction. Incorporation of drugs like antibiotics and bone morphogenetic protein is envisaged. Load-bearing applications are allowed for CHDA-type, CA-type and HA-type CPBCs as they have a higher compressive strength than human trabecular bone (10 MPa).  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号